Fresenius Targets Actavis With IP Suit Over Diprivan

Law360, New York (June 7, 2013, 1:45 PM EDT) -- Fresenius Kabi USA LLC launched a suit in Delaware federal court Thursday alleging Actavis Inc. and its subsidiary Watson Laboratories infringed four patents by attempting to market a generic form of the sedative and anesthetic Diprivan.

According to the subsidiary of Germany-based Fresenius SE & Co. KGaA, Watson and Actavis violated the patents — all covering compositions of edetate and the sedating, hypnotic agent propofol — when they filed an abbreviated new drug application with the U.S. Food and Drug Administration for approval of their generic....
To view the full article, register now.